DULAGLUTIDE (Trulicity) prior authorization at Humana

The PA criteria you'll need to meet

Humana reviews DULAGLUTIDE (Trulicity) prior authorizations against its medical policy for GLP-1 Receptor Agonist. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

Documentation packet checklist

• Chart note with diagnosis (ICD-10 code) and clinical severity markers
• Documented failure of, contraindication to, or intolerance of step-therapy alternatives in GLP-1 Receptor Agonist
• Prior treatment history including dosing, duration, and reason for discontinuation
• Relevant labs, imaging, or assessment scores supporting medical necessity
• Prescriber attestation linking the FDA-approved indication to the patient's presentation
• Humana's medical policy URL referenced in the cover letter

Humana's common denial patterns

Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

DULAGLUTIDE (Trulicity)-specific denial patterns and context

Across payers (not just Humana), DULAGLUTIDE (Trulicity)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:

• Step therapy requiring semaglutide or tirzepatide first (clinically-preferred per ADA 2024)
• Non-formulary tier 4 specialty
• Quantity limit on weekly pen
• Prior auth requiring A1C ≥7.5% documentation

Brand: Trulicity. Once-weekly GLP-1 for T2D. REWIND trial established CV risk reduction in T2D with or without established CV disease. Often displaced as plans prefer semaglutide or tirzepatide.

Manufacturer patient-assistance program: Lilly Cares Foundation — relevant when a Humana denial sticks and the patient needs bridge access while appealing.

How Humana approaches GLP-1 receptor agonists PAs

Humana's GLP-1 receptor agonists reviewer typically anchors DULAGLUTIDE (TRULICITY) prior-auth decisions on ma plan step therapy on part b drugs and prior auth on specialty drugs. Pharmacy-benefit review for DULAGLUTIDE (TRULICITY) at Humana is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. Plans including Humana commonly distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda) — the second path triggers benefit-exclusion review under the plan's anti-obesity-medication carve-out language. Humana is domiciled in KY, so unresolved appeals escalate to the KY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Heavily Medicare Advantage focused.

If the PA is denied

Humana gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus a peer-reviewed citation supporting DULAGLUTIDE (Trulicity)for the patient's indication.

Medicare Advantage path: if Humana misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.

Humana as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. For DULAGLUTIDE (TRULICITY), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.

Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Humana denial on DenialHelp.

Contact Humana

• Provider portal: https://www.humana.com/provider